GlassScriptPhysician profile
Lawrence R Blum
NPI 1811082571
$5,128.58
in general payments reported to CMS, 2019-2025
25 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $487 · 2021: $667 · 2022: $806 · 2023: $981 · 2024: $547 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,047.47 | 2019-2025 | Argos, Clareon, Simbrinza |
| Sun Pharmaceutical Industries INC. | $691.85 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $518.13 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $340.16 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Optinose US, INC. | $331.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $283.97 | 2019-2023 | |
| Allergan, INC. | $231.10 | 2019-2021 | |
| Harrow Eye, LLC | $192.58 | 2025 | Vevye |
| Dompe US, INC. | $183.65 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $153.76 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $147.04 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $134.14 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $119.84 | 2021-2023 | Tearcare System |
| Abbvie INC. | $117.58 | 2022-2025 | |
| Shire North American Group INC | $77.76 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $76.69 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.11 | 2019-2021 | |
| Amgen INC. | $75.30 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $74.27 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $73.53 | 2021-2025 | Dupixent |
| Horizon Therapeutics Plc | $67.20 | 2021-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $49.22 | 2020-2021 | |
| Ivantis, INC | $24.73 | 2021 | |
| Merck Sharp & Dohme LLC | $20.91 | 2023 | |
| Hikma Pharmaceuticals USA | $20.28 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.